On Demand OCD Lecture Series: The Role of Medications in Pediatric Obsessive-Compulsive Disorder: Water Wings for Behavioral Therapy
This presentation was originally reviewed on September 16, 2021, and broadcast live online on September 17, 2021, from 10:45 AM - 12:15 PM ET.
The views and opinions expressed by this presenter in this lecture are their own, and do not represent the views of Sheppard Pratt.
Obsessive-Compulsive Disorder (OCD) can be a severely impairing condition but is highly responsive to specialized care. There is a substantial evidence base demonstrating the best approaches to treating OCD; therefore, it is critical that clinicians are informed of strategies that do and don’t work. While exposure-response prevention (ERP) is the gold-standard treatment for OCD, many patients cannot adequately engage in treatment without the help of pharmacotherapy. Medications can help patients be willing to begin therapy, tolerate exposures without getting overwhelmed, and move efficiently through an exposure hierarchy. Evidence shows that outcomes are significantly improved when medications are used in conjunction with ERP. While SSRIs represent the single first-line medication class, strategies for SSRI augmentation or second- and third-line approaches are more complex. The majority of patients presenting to our intensive outpatient program have not received adequate CBT or pharmacotherapeutic care. Experience with severe OCD is often limited in training and specialized education is necessary for providers to be well-equipped to effectively treat the full range of OCD manifestations.
This activity is intended for physicians, nurses, psychologists, social workers, counselors, and other mental health professionals.
After this lecture, registrants will be able to:
- Determine the need for pharmacotherapy for OCD and choose a first-line medication.
- Identify the evidence-based augmentation options when first-line treatment is insufficient.
- Appreciate and leverage the synergy between CBT and pharmacotherapy in the treatment of OCD.
There is no commercial support for this activity.
About these speakers
Erika Nurmi, MD, PhD received her MD/PhD from Vanderbilt University and her clinical training in adult, child and adolescent psychiatry from UCLA. She is currently Associate Professor of Psychiatry and Biobehavioral Sciences in the UCLA Division of Child and Adolescent Psychiatry. In both research and clinical practice, Dr. Nurmi specializes in obsessive-compulsive and tic disorders. She is Medical Director of the Pediatric OCD Intensive Outpatient Program, a part of the UCLA Childhood OCD, Anxiety, and Tic Disorders Program. At the Greater Los Angeles VA, partner to UCLA, she is the Anxiety Disorders Section Chief. Dr. Nurmi directs a molecular and computational genetics laboratory, investigating genetic contributions to mental illness vulnerability and response to treatment. She is an executive member of the OCD/Tourette Working Group of the Psychiatric Genomics Consortium and UCLA site Principal Investigator for the International OCD ENIGMA Consortium. Dr. Nurmi is a national and international speaker in educational forums, clinician trainings, parent/patient support groups and public events, where she enjoys sharing her passion for science and medicine.
Sheppard Pratt holds the standard that its continuing medical education programs should be free of commercial bias and conflict of interest. In accord with Sheppard Pratt's Disclosure Policy, as well as standards of the Accreditation Council for Continuing Medical Education (ACCME) and the American Medical Association (AMA), all planners, reviewers, speakers and persons in control of content have been asked to disclose any relationship he /she (or a partner or spouse) has with any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients, during the past 12 months. All planners, reviewers and speakers have also been asked to disclose any payments accepted for this lecture from any entity besides Sheppard Pratt, and if there will be discussion of any products, services or off-label uses of product(s) during this presentation.
Erika Nurmi, MD, PhD, reports that she is on the Medical Advisory Board of the Tourette Association of America & Teva Pharmaceuticals and Scientific Advisory Board of Myriad Genetics. She will discuss genetic testing to inform prescribing, and off label uses of augmentation drugs & new alternatives not FDA-approved for OCD but well-supported by literature, in this presentation.
Event Planners/Reviewers Disclosures: The following event planners and/or reviewers are reported as having no financial interest, arrangement or affiliation with any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients, during the past 12 months: Jon Hershfield, MFT, Todd Peters, MD, Deepak Prabhakar, MD, Briana Riemer, MD, Louis Marino, MD, Ehsan Syed, MD, Devi Bhuyan, PhD, Faith Dickerson, PhD, Carrie Etheridge, LCSW-C, Tom Flis, LCPC, Laura Webb, RN-BC, MSN, Bruce Boxer, PhD, MBA, MA, MSN, RN, NPD-BC, NEA-BC, MCHES, CPHQ, Stacey Garnett, RN, MSN, Heather Billings, RN, Lisa Illum, MLIS, MEd, and Jennifer Tornabene.
Physician Statement: Sheppard Pratt is accredited by The Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Sheppard Pratt takes responsibility for the content, quality, and scientific integrity of this CME activity. Sheppard Pratt designates this enduring activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurse Statement: Sheppard Pratt is approved as a provider of nursing continuing professional development by the Maryland Nurses Association, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation. Sheppard Pratt takes responsibility for the content, quality, and scientific integrity of this CME activity. This activity provides 1.5 contact hours for nurses.
Psychologist Statement: Sheppard Pratt is authorized by the State Board of Examiners of Psychologists as a sponsor of continuing education. Sheppard Pratt takes responsibility for the content, quality, and scientific integrity of this CE activity. Sheppard Pratt designates this educational activity for a maximum of 1.5 contact hours for Psychologists.
Social Worker Statement: Sheppard Pratt is authorized by the Board of Social Work Examiners of Maryland to offer continuing education for Social Workers. Sheppard Pratt takes responsibility for the content, quality, and scientific integrity of this CME activity. This activity is approved for 1.5 contact hours in Category II credits for Social Workers.
Counselor Statement: Sheppard Pratt has been approved by NBCC as an Approved Continuing Education Provider, ACEP No. 5098. Programs that do not qualify for NBCC credit are clearly identified. Sheppard Pratt is solely responsible for all aspects of the program. This activity is available for 1.5 NBCC clock hours.
- 1.50 ACEP NBCC clock hours
- 1.50 AMA PRA Category 1 Credit™
- 1.50 Category II credits for Social Workers
- 1.50 Psychologists
- 1.50 MNA Contact Hours for Nurses
- 1.50 Participation
ON DEMAND WEBINAR: FOR BEST RESULTS WATCH USING GOOGLE CHROME
OCD & Anxiety Lecture Series: The Role of Medications in Pediatric Obsessive-Compulsive Disorder: Water Wings for Behavioral Therapy
Erika Nurmi, MD, PhD
Assistant Professor of Psychiatry and Biobehavioral Sciences
Division of Child and Adolescent Psychiatry
David Geffen School of Medicine
Medical Director, UCLA Pediatric OCD Intensive Outpatient Program
Los Angeles, CA
Originally reviewed September 16, 2021
Originally broadcast live September 17, 2021, from 10:45 am - 12:15 pm ET
Enduring Activity Credit Expiration Date: Wednesday, January 31, 2024
Activity Time: One hour recorded webinar lecture with a 15-minute evaluation process. Total Time: 1:45
TO EARN CONTINUING EDUCATION CREDIT FOR YOUR ATTENDANCE
On the OVERVIEW or REGISTER/TAKE COURSE tab, select the GREEN RECTANGLE, TAKE COURSE to begin.
Complete the Pretest and select NEXT in the bottom right corner of the screen. Use the NEXT button for best results.
The PowerPoint handout will be available for download.
After downloading the handout, select NEXT to begin and watch the one-hour video.
You may need to select play for the video to begin.
After the video follow the prompts to complete the posttest, evaluation and attestation of credit.
Once you have completed all the components of the Course Progress bar, the certificate will be immediately downloadable.
There is no commercial support for this activity.
Optimal System Configuration
Flash Player: Adobe Flash Player 10.1+
Browser: Firefox 3+, Internet Explorer 8.0+, Safari 4.0+, or Google Chrome 7.0+
Operating System: Windows XP+ or Mac OS X 10.4+
Internet Connection: 1 Mbps or higher
Windows PC: 500-MHz Pentium II; Windows XP or higher; 128 MB RAM; Video Card at least 64MB of video memory; Sound Card at least 16-bit; Macromedia Flash Player 10 or higher, audio playback with speakers for programs with video content; Firefox 1.1+, Internet Explorer 7.0+, Safari 1.0+, Google Chrome, or Opera
Macintosh: Mac OS X 10.3 or higher with latest updates installed; 1.83MHz Intel Core Duo or faster; RAM: 128MB or more; Video Card: at least 64MB of video memory; Sound Card: at least 16-bit